Table 4 Emphasis on ongoing clinical trials comprising drug combinations for skin cancer management
NCT Number | Study Title | Phase | Completion of Study | Current state |
|---|---|---|---|---|
NCT03524326 | 5-Fluorouracil and Calcipotriene for Treatment of Low-Grade Skin Cancer | Phase 2 Phase 3 | June 2025 | Active, not recruiting |
NCT03524326 | Testing Lenvatinib and Cetuximab in Patients with Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | Phase 1 | April 2023 | Active, not recruiting |
NCT03944941 | Avelumab With or Without Cetuximab in Treating Patients with Advanced Skin Squamous Cell Cancer | Phase 2 | December 2023 | Recruiting |
NCT02324608 | Cetuximab Before Surgery in Treating Patients with Aggressive Locally Advanced Skin Cancer | Not applicable | December 2022 | Active, not recruiting |
NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Phase 2 | May 2023 | Active, not recruiting |
NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants with Advanced or Refractory Rare Tumors | Phase 2 | July 30, 2022 | No result posted |
NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients with Advanced Solid Tumors | Phase 1 | July 31, 2024 | Recruiting |
NCT02955290 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients with Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | Phase 1 Phase 2 | December 9, 2023 | Recruiting |
NCT04234113 | Study of SO-C101 and SO-C101 in Combination with Pembro in Adult Patients with Advanced/Metastatic Solid Tumors | Phase 1 | December 2023 | Recruiting |
NCT03590054 | Abexinostat in Combination with Pembrolizumab in Patients with Advanced Solid Tumor Malignancies | Phase 1 | November 30, 2023 | Active, not recruiting |
NCT03684785 | Intratumoral Cavrotolimod Combined with Pembrolizumab or Cemiplimab in Patients with Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors | Phase 1 Phase 2 | March 30, 2022 | Terminated due to administrative reasons |
NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Phase 2 | May 2023 | Active, not recruiting |
NCT03816332 | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers | Phase 1 | May 30, 2023 | Suspended |
NCT02955290 | CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients with Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer | Phase 1 Phase 2 | December 9, 2023 | Recruiting |
NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination with Nivolumab | Phase 2 | November 2024 | Recruiting |
NCT04050436 | Study Evaluating Cemiplimab Alone and Combined with RP1 in Treating Advanced Squamous Skin Cancer | Phase 2 | March 2025 | Recruiting |
NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination with Tislelizumab in Patients with Select Advanced Cancers | Phase 1 | September 15, 2025 | Not yet recruiting |
NCT05220748 | RM-1995 Photoimmunotherapy, as Monotherapy or Combined with Pembrolizumab, in Patients with Advanced CuSCC and HNSCC | Phase 1 | September 2024 | Recruiting |
NCT02419495 | Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients with Advanced Malignancies | Phase 1 | December 31, 2022 | Recruiting |
NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients with Recurrent or Refractory Solid Tumors or Sarcomas | Phase 1 Phase 2 | October 5, 2022 | Active, not recruiting |
NCT02159066 | LGX818 and MEK162 in Combination with a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma | Phase 2 | January 17, 2023 | Active, not recruiting |
NCT04835805 | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma | Phase 1 | November 11, 2024 | Recruiting |
NCT04526899 | Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients with Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | Phase 2 | June 2025 | Recruiting |
NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination with Investigational Agents in Participants with Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | Phase 1 Phase 2 | April 3, 2030 | Recruiting |
NCT04305054 | Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination with Investigational Agents or Pembrolizumab Alone in Participants with First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | Phase 1 Phase 2 | April 3, 2030 | Recruiting |
NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination with Investigational Agents or Pembrolizumab Alone in Participants with Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | Phase 1 Phase 2 | April 3, 2030 | Recruiting |
NCT04700072 | Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination with Investigational Agents or Pembrolizumab Alone in Participants with Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | Phase 1 Phase 2 | April 3, 2030 | Recruiting |
NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination with Intravenous Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors | Phase 1 Phase 2 | October 31, 2024 | Recruiting |
NCT04674683 | Study Comparing Investigational Drug HBI-8000 Combined with Nivolumab vs. Nivolumab in Patients with Advanced Melanoma | Phase 3 | October 2025 | Recruiting |
NCT04835805 | A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination with Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma | Phase 1 | November 11, 2024 | Recruiting |
NCT04526899 | Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients with Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma | Phase 2 | June 2025 | Recruiting |
NCT04557956 | Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment | Phase 1 Phase 2 | December 4, 2024 | Recruiting |
NCT04157517 | A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together with Pembrolizumab in Adults with Metastatic Solid Tumors | Phase 1 Phase 2 | August 2, 2023 | Recruiting |
NCT04993677 | A Study of SEA-CD40 Given with Other Drugs in Cancers | Phase 2 | October 31, 2025 | Recruiting |
NCT02857270 | A Study of LY3214996 Administered Alone or in Combination with Other Agents in Participants with Advanced/Metastatic Cancer | Phase 1 | July 31, 2023 | Active, not recruiting |
NCT03776136 | Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902–004/E7080-G000-225/LEAP-004) | Phase 2 | December 26, 2024 | Active, not recruiting |
NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination with Nivolumab | Phase 2 | November 2024 | Recruiting |
NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination with PDR001 in Patients with Advanced Solid Tumors | Phase 1 | April 15, 2024 | Recruiting |
NCT04894994 | FLX475 in Combination with Ipilimumab in Advanced Melanoma | Phase 2 | December 1, 2023 | Recruiting |
NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and KFA115 in Combination with Tislelizumab in Patients with Select Advanced Cancers | Phase 1 | September 15, 2025 | Not yet recruiting |
NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients with Advanced Cancer and HIV | Phase 1 | November 2, 2025 | Recruiting |
NCT03289962 | A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination with Atezolizumab in Participants with Locally Advanced or Metastatic Tumors | Phase 1 | February 1, 2024 | Active, not recruiting |
NCT02791334 | A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination with Participants with Advanced Refractory Solid Tumors | Phase 1 | December 6, 2022 | Active, not recruiting |
NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 Phase 2 | May 2023 | Recruiting |
NCT02419495 | Selinexor With Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients with Advanced Malignancies | Phase 1 | December 31, 2022 | Recruiting |
NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults with Advanced Solid Malignancies | Phase 1 | March 2025 | Recruiting |
NCT04140526 | Safety, PK, and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | Phase 1 Phase 2 | December 31, 2024 | Recruiting |
NCT04336241 | Study of RP2 Monotherapy and RP2 in Combination with Nivolumab in Patients with Solid Tumors | Phase 1 | July 223 | Recruiting |
NCT05259696 | Glycan Mediated Immune Regulation with a Bi-Sialidase Fusion Protein (GLIMMER-01) | Phase 1 Phase 2 | June 2025 | Recruiting |
NCT04165967 | Adoptive Tumor-infiltrating Lymphocyte Transfer with Nivolumab for Melanoma | Phase 1 | August 2025 | Recruiting |